Office evaluation and management of bladder neoplasms

M. J. Young, M. S. Soloway

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Transitional cell carcinoma is the predominant bladder neoplasm. These tumors are heterogeneous, and the risk of recurrence and progression should guide further management. When this approach is used, patients at lower risk avoid the morbidity and expense of unnecessary interventions and tests, whereas higher-risk patients are treated more aggressively. Cystoscopy and IVP remain the standard initial evaluation for patients suspected of having a bladder neoplasm. Intravesical chemotherapy and immunotherapy can be administered safely in the office to reduce disease recurrence when appropriate. The advent of lasers has permitted fulgaration of low-grade neoplasms in the office with local anesthesia. Surveillance of patients with superficial disease is still largely dependent on office-based cystoscopy. Tumor markers for the identification of recurrent disease are being investigated and may prove useful to reduce the number of negative cystoscopic evaluations performed for surveillance. Patients postcystectomy are followed up with attention to detection of recurrent disease in remnant urothelium, metastatic disease, and metabolic and nutritional disturbances, which may result from urinary diversion.

Original languageEnglish
Pages (from-to)603-611
Number of pages9
JournalUrologic Clinics of North America
Volume25
Issue number4
StatePublished - Nov 20 1998
Externally publishedYes

Fingerprint

Office Management
Urinary Bladder Neoplasms
Cystoscopy
Nutritional and Metabolic Diseases
Recurrence
Urothelium
Urinary Diversion
Transitional Cell Carcinoma
Local Anesthesia
Tumor Biomarkers
Immunotherapy
Neoplasms
Lasers
Morbidity
Drug Therapy

ASJC Scopus subject areas

  • Urology

Cite this

Young, M. J., & Soloway, M. S. (1998). Office evaluation and management of bladder neoplasms. Urologic Clinics of North America, 25(4), 603-611.

Office evaluation and management of bladder neoplasms. / Young, M. J.; Soloway, M. S.

In: Urologic Clinics of North America, Vol. 25, No. 4, 20.11.1998, p. 603-611.

Research output: Contribution to journalArticle

Young, MJ & Soloway, MS 1998, 'Office evaluation and management of bladder neoplasms', Urologic Clinics of North America, vol. 25, no. 4, pp. 603-611.
Young, M. J. ; Soloway, M. S. / Office evaluation and management of bladder neoplasms. In: Urologic Clinics of North America. 1998 ; Vol. 25, No. 4. pp. 603-611.
@article{e88b13f8ea65481ca6ce0fa958d2e8ae,
title = "Office evaluation and management of bladder neoplasms",
abstract = "Transitional cell carcinoma is the predominant bladder neoplasm. These tumors are heterogeneous, and the risk of recurrence and progression should guide further management. When this approach is used, patients at lower risk avoid the morbidity and expense of unnecessary interventions and tests, whereas higher-risk patients are treated more aggressively. Cystoscopy and IVP remain the standard initial evaluation for patients suspected of having a bladder neoplasm. Intravesical chemotherapy and immunotherapy can be administered safely in the office to reduce disease recurrence when appropriate. The advent of lasers has permitted fulgaration of low-grade neoplasms in the office with local anesthesia. Surveillance of patients with superficial disease is still largely dependent on office-based cystoscopy. Tumor markers for the identification of recurrent disease are being investigated and may prove useful to reduce the number of negative cystoscopic evaluations performed for surveillance. Patients postcystectomy are followed up with attention to detection of recurrent disease in remnant urothelium, metastatic disease, and metabolic and nutritional disturbances, which may result from urinary diversion.",
author = "Young, {M. J.} and Soloway, {M. S.}",
year = "1998",
month = "11",
day = "20",
language = "English",
volume = "25",
pages = "603--611",
journal = "Urologic Clinics of North America",
issn = "0094-0143",
publisher = "W.B. Saunders Ltd",
number = "4",

}

TY - JOUR

T1 - Office evaluation and management of bladder neoplasms

AU - Young, M. J.

AU - Soloway, M. S.

PY - 1998/11/20

Y1 - 1998/11/20

N2 - Transitional cell carcinoma is the predominant bladder neoplasm. These tumors are heterogeneous, and the risk of recurrence and progression should guide further management. When this approach is used, patients at lower risk avoid the morbidity and expense of unnecessary interventions and tests, whereas higher-risk patients are treated more aggressively. Cystoscopy and IVP remain the standard initial evaluation for patients suspected of having a bladder neoplasm. Intravesical chemotherapy and immunotherapy can be administered safely in the office to reduce disease recurrence when appropriate. The advent of lasers has permitted fulgaration of low-grade neoplasms in the office with local anesthesia. Surveillance of patients with superficial disease is still largely dependent on office-based cystoscopy. Tumor markers for the identification of recurrent disease are being investigated and may prove useful to reduce the number of negative cystoscopic evaluations performed for surveillance. Patients postcystectomy are followed up with attention to detection of recurrent disease in remnant urothelium, metastatic disease, and metabolic and nutritional disturbances, which may result from urinary diversion.

AB - Transitional cell carcinoma is the predominant bladder neoplasm. These tumors are heterogeneous, and the risk of recurrence and progression should guide further management. When this approach is used, patients at lower risk avoid the morbidity and expense of unnecessary interventions and tests, whereas higher-risk patients are treated more aggressively. Cystoscopy and IVP remain the standard initial evaluation for patients suspected of having a bladder neoplasm. Intravesical chemotherapy and immunotherapy can be administered safely in the office to reduce disease recurrence when appropriate. The advent of lasers has permitted fulgaration of low-grade neoplasms in the office with local anesthesia. Surveillance of patients with superficial disease is still largely dependent on office-based cystoscopy. Tumor markers for the identification of recurrent disease are being investigated and may prove useful to reduce the number of negative cystoscopic evaluations performed for surveillance. Patients postcystectomy are followed up with attention to detection of recurrent disease in remnant urothelium, metastatic disease, and metabolic and nutritional disturbances, which may result from urinary diversion.

UR - http://www.scopus.com/inward/record.url?scp=0031734661&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031734661&partnerID=8YFLogxK

M3 - Article

C2 - 10026769

AN - SCOPUS:0031734661

VL - 25

SP - 603

EP - 611

JO - Urologic Clinics of North America

JF - Urologic Clinics of North America

SN - 0094-0143

IS - 4

ER -